Last reviewed · How we verify
NCT07004244
Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies
Phase 1 trial testing KRAS-mutated mRNA vaccine in Malignant Tumors in 20 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | Sichuan University |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 5 June 2025 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- KRAS-mutated mRNA vaccine — full drug profile →
- TORIPALIMAB (TORIPALIMAB) — full drug profile →
- Pemetrexed+carboplatin
Conditions studied
- Malignant Tumors — all drugs for Malignant Tumors →
Sponsor
Sichuan University
Who can join
18 and older, any sex, with Malignant Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to evaluate the safety and efficacy of mRNA vaccine for the KRAS mutation malignant tumors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07004244
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Malignant Tumors
Currently open trials in the same condition.
- NCT07112222 — A Study of LM-350 in Subjects With Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
- NCT07301801 — Clinical Application of 68Ga-FL-031 PET in the Diagnosis and Staging of Malignant Tumors · EARLY_PHASE1 · recruiting
- NCT06944444 — A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors · Phase 1 · recruiting
- NCT05714748 — Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors · Phase 1 · active not recruiting
- NCT05615974 — A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors · Phase 1, PHASE2 · recruiting
Other Sichuan University trials
Trials by the same sponsor.
- NCT07501169 — Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lun · Phase 2 · not yet recruiting
- NCT07362732 — Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection · EARLY_PHASE1 · not yet recruiting
- NCT07374250 — Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma · Phase 2 · not yet recruiting
- NCT07332663 — Exploratory Study on the Treatment of Relapsed and Refractory B-cell Malignant Tumors With WGb-0301 Injection · EARLY_PHASE1 · not yet recruiting
- NCT07258147 — Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07004244 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sichuan University
- Last refreshed: 24 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07004244.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing